Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an update.
Radiopharm Theranostics Limited has announced a change in the substantial holding of Paul Hopper, a significant shareholder. The change, effective from October 24, 2025, reflects a decrease in his voting power from 6.9% to 5.3%, following a dilution through placement. This adjustment in shareholding may impact the company’s governance dynamics and shareholder influence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology sector, focusing on the development of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on the Australian Securities Exchange under the ticker RAD.
Average Trading Volume: 6,090,118
Technical Sentiment Signal: Buy
Current Market Cap: A$72.3M
Learn more about RAD stock on TipRanks’ Stock Analysis page.